{"id":"triamcinolone-acetonide-0-1-oint","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Systemic absorption (with prolonged use or occlusion)"}]},"_chembl":{"chemblId":"CHEMBL1504","moleculeType":"Small molecule","molecularWeight":"434.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug translocates to the nucleus and modulates gene transcription, reducing production of pro-inflammatory cytokines, chemokines, and adhesion molecules. This leads to decreased inflammation, reduced immune cell infiltration, and suppression of local inflammatory responses at the site of application. As a topical ointment formulation, it provides localized anti-inflammatory and immunosuppressive effects on the skin.","oneSentence":"Triamcinolone acetonide is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the cytoplasm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:24.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)"},{"name":"Allergic contact dermatitis"},{"name":"Lichen planus"}]},"trialDetails":[{"nctId":"NCT05436535","phase":"PHASE4","title":"Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-21","conditions":"Atopic Dermatitis","enrollment":433},{"nctId":"NCT06988527","phase":"PHASE2, PHASE3","title":"Treatment Outcomes and Patient Satisfaction of Oral Lichen Planus Treatment","status":"RECRUITING","sponsor":"Dar Al Uloom University","startDate":"2025-05-20","conditions":"Erosive Oral Lichen Planus, Atrophic Lichen Planus","enrollment":56},{"nctId":"NCT06362005","phase":"PHASE4","title":"The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-05-01","conditions":"Lichen Planus, Oral","enrollment":50},{"nctId":"NCT03568318","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-09","conditions":"Atopic Dermatitis","enrollment":1533},{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT03380026","phase":"PHASE2","title":"Mechlorethamine Induced Contact Dermatitis Avoidance Study","status":"COMPLETED","sponsor":"Rochester Skin Lymphoma Medical Group, PLLC","startDate":"2017-12-13","conditions":"Cutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I, Mycosis Fungoides","enrollment":28},{"nctId":"NCT04008784","phase":"","title":"Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period","status":"COMPLETED","sponsor":"Clinical Research Center of the Carolinas","startDate":"2019-09-16","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT02260986","phase":"PHASE3","title":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-09","conditions":"Atopic Dermatitis","enrollment":740},{"nctId":"NCT01675232","phase":"NA","title":"A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-07","conditions":"Atopic Dermatitis","enrollment":45},{"nctId":"NCT01524744","phase":"PHASE2","title":"A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2009-03","conditions":"Oral Lichen Planus","enrollment":40},{"nctId":"NCT00779792","phase":"PHASE4","title":"Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2008-09","conditions":"Dermatitis, Contact, Dermatitis, Occupational","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group I"],"phase":"marketed","status":"active","brandName":"Triamcinolone Acetonide 0.1% Oint","genericName":"Triamcinolone Acetonide 0.1% Oint","companyName":"Al-Azhar University","companyId":"al-azhar-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone acetonide is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis), Allergic contact dermatitis, Lichen planus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}